MUTUAL FUNDS: Gloves Off

SEBI and fund companies are  speaking up about each other

Now that the law ministry and...

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation
TAXATION: BCCI’s Doosra to Taxman

The world’s richest cricketing body is finding new loopholes to remain a charitable organisation

Premium Content
Monthly Digital Access

Subscribe

Already A Subscriber?
Login
Yearly Digital+Print Access

Subscribe

Moneylife Magazine Subscriber or MSSN member?
Login

Yearly Subscriber Login

Enter the mail id that you want to use & click on Go. We will send you a link to your email for verficiation
US court dismisses Taro's attempt to block open offer: Sun

Earlier, the open offer was challenged in the Israeli Supreme Court, which prohibited the Mumbai-based company from closing the offer until a ruling was delivered in other cases related to the takeover

Indian pharmaceutical major Sun Pharmaceutical today said that a US court has dismissed a litigation filed by Israeli drug firm Taro to block an open offer launched by the domestic pharma major to acquire shares of the Tel Aviv-based company, reports PTI.

"The US district court for the Southern District of New York had dismissed in its entirety the complaint filed by Taro Pharmaceutical Industries Ltd, seeking to block the tender offer by Sun's subsidiary Alkaloida Chemical Company Exclusive Group Ltd to purchase all outstanding ordinary shares of Taro," Sun Pharmaceutical said in a statement.

Sun Pharma is the single-largest shareholder in Taro with over 35% stake. It has been trying to wrest control over Taro ever since its $454-million merger deal in 2007 was unilaterally terminated by the Israeli firm a year later, citing undervaluation.

After this, both the companies filed cases against each other and the matter lay pending in the Israeli Supreme Court.

Alkaloida Chemical had launched an open offer in 2008 for acquiring additional shares of Taro. After this, Taro had filed litigation against the Indian firm in a US district court to block its open offer.

"The court also dismissed Taro's other claims, including breach of contract and misappropriation of trade secrets, for lack of subject matter jurisdiction," the statement said.

The Indian firm claimed that the court has given two weeks' time to Taro for filing an amended complaint in an attempt to fix the defects in its earlier petition.

"However, even if Taro revives its state law claims, it will not entitle Taro to obtain the injunction it was seeking to enjoin consummation of Alkaloida's offer," Sun Pharma claimed.

Earlier, the open offer was challenged in the Israeli Supreme Court, which prohibited the Mumbai-based company from closing the offer until a ruling was delivered in other cases related to the takeover.

Sun said Alkaloida's offer remains subject to a continuing order issued by the Supreme Court of Israel, temporarily prohibiting the closing of the offer until the court issues a decision on the appeal of a separate litigation commenced against Alkaloida and its affiliates by Taro.

Commenting on the development, Sun Pharma chairman and managing director Dilip Shanghvi said, "Sun is pleased, but not surprised, by this decision."

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)